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Cell proliferation requires nutrients, energy, and biosynthetic activity to duplicate all macromolecular compo-
nents during each passage through the cell cycle. It is therefore not surprising that metabolic activities in pro-
liferating cells are fundamentally different from those in nonproliferating cells. This review examines the idea
that several core fluxes, including aerobic glycolysis, de novo lipid biosynthesis, and glutamine-dependent
anaplerosis, form a stereotyped platform supporting proliferation of diverse cell types. We also consider
regulation of these fluxes by cellular mediators of signal transduction and gene expression, including the
phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR system, hypoxia-inducible factor 1 (HIF-1), and Myc, during
physiologic cell proliferation and tumorigenesis.Introduction
In mammals, cell proliferation is required for embryogenesis,
growth, proper function of several adult tissues, and tumorigen-
esis. A primary focus of research on cell proliferation has been
understanding the mechanisms that regulate the proliferative
state, work that has led to identification of growth-factor signal
transduction pathways and transcriptional networks enabling
cells to initiate and maintain cell cycling. But the onset of prolif-
eration introduces important problems in cellular metabolism as
well, because each passage through the cell cycle yields two
daughter cells and requires a doubling of total biomass (proteins,
lipids, and nucleic acids). This poses a profound metabolic chal-
lenge that must be met if cells are to respond to proliferative
stimuli.
Proliferating cells often take up nutrients in excess of bioener-
getic needs and shunt metabolites into pathways that support
a platform for biosynthesis (Bauer et al., 2004). Signals that stim-
ulate cell proliferation must also participate in the reorganization
of metabolic activity that allows quiescent cells to begin to pro-
liferate (Figure 1). Over the past several decades, a consistent
picture of intermediary metabolism has emerged from studies
on diverse types of proliferating cells. Metabolism in these cells
differs from quiescent cell metabolism by high rates of glycoly-
sis, lactate production, and biosynthesis of lipids and other mac-
romolecules (Figure 2). In this review, we focus on the roles of
these metabolic activities and the replenishment of intermedi-
ates for the tricarboxylic acid (TCA) cycle (anaplerosis) during
proliferation. We also discuss current concepts regarding how
signal transduction pathways influence cell metabolism.
Most of the work cited below involves proliferating lympho-
cytes or tumor cells. Lymphocytes and other hematopoietic cells
are excellent models for the study of metabolic regulation be-
cause quiescent cells can be stimulated to proliferate in vitro
and the signaling mechanisms behind cell proliferation are well
characterized. Tumor cells are also useful because a wide variety
of cell lines are available and the genetic mechanisms leading to
tumorigenesis are often known. It should be stressed that ‘‘tumormetabolism’’ is not synonymous with the metabolism of cell pro-
liferation. While proliferation is required for tumors to grow, many
factors within the tumor microenvironment can influence cellular
metabolism, resulting in heterogeneous metabolic activity. Our
interest in tumor cells as discussed here involves the metabolic
activities that promote their growth and proliferation.
Proliferating Cells Use Aerobic Glycolysis
In the 1920s, Otto Warburg published the seminal observation
that rapidly proliferating ascites tumor cells consume glucose
at a surprisingly high rate compared to normal cells and secrete
most of the glucose-derived carbon as lactate rather than oxidiz-
ing it completely, a phenomenon known as the ‘‘Warburg effect’’
(Warburg, 1925, 1956b). This observation presented a paradox
that still has not been completely resolved: Why do proliferating
cells, which ostensibly have a great need for ATP, use such
a wasteful form of metabolism? Warburg proposed that tumor
cells harbor a permanent impairment of oxidative metabolism
resulting in a compensatory increase in glycolytic flux (Warburg,
1956a). But later studies on proliferating primary lymphocytes
revealed similar patterns, in which more than 90% of glucose
carbon was converted to lactate, ruling out the possibility that
aerobic glycolysis is unique to tumor cells or that the Warburg ef-
fect only develops when oxidative capacity is damaged (Brand,
1985; Hedeskov, 1968; Roos and Loos, 1973; Wang et al., 1976).
Indeed, many highly proliferative tumor cell lines that have been
carefully studied do not have defects in oxidative metabolism
(Moreno-Sanchez et al., 2007).
So why does the Warburg effect occur? Clearly, the high gly-
colytic rate provides several advantages for proliferating cells.
First, it allows cells to use the most abundant extracellular nutri-
ent, glucose, to produce abundant ATP. Although the yield of
ATP per glucose consumed is low, if the glycolytic flux is high
enough, the percentage of cellular ATP produced from glycolysis
can exceed that produced from oxidative phosphorylation
(Guppy et al., 1993; Warburg, 1956b). This may be due to the
high rate of ATP production during glycolysis compared toCell Metabolism 7, January 2008 ª2008 Elsevier Inc. 11
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ReviewFigure 1. Growth-Factor Signaling Regulates the Uptake and Metabolism of Extracellular Nutrients
At rest, basal levels of lineage-specific growth-factor signaling (green) allow cells to take up sufficient nutrients like glucose (red) and amino acids (blue) in order to
provide the low levels of ATP production and macromolecular synthesis needed to maintain cellular homeostasis. In the absence of any extrinsic signals (no li-
gand), mammalian cells lose surface expression of nutrient transporters. To survive in the absence of the ability to take up extracellular nutrients, growth-factor-
deprived cells engage in autophagic degradation of macromolecules and organelles. This is a finite survival strategy, ultimately resulting in cell death. In contrast,
increases in ligand signaling instruct cells to begin taking up nutrients at a high rate and to allocate them into metabolic pathways that support production of ATP
and macromolecules like proteins, lipids, and nucleic acids. These activities culminate in a net increase in cellular biomass (growth) and, ultimately, the formation
of daughter cells.oxidative phosphorylation (Pfeiffer et al., 2001). Second, glucose
degradation provides cells with intermediates needed for bio-
synthetic pathways, including ribose sugars for nucleotides;
glycerol and citrate for lipids; nonessential amino acids; and,
through the oxidative pentose phosphate pathway, NADPH. So
the Warburg effect benefits both bioenergetics and biosynthesis.
What remains controversial about the Warburg effect is why
the rate of lactate production is so high when more of the pyru-
vate could presumably be oxidized to enhance ATP production.
One explanation is simply that glycolysis outpaces the maximal
velocity of pyruvate oxidation, so that cells must instead elimi-
nate pyruvate using high-flux mechanisms. Oxidation of pyru-
vate requires import into the mitochondrial matrix, followed by
activity of highly regulated enzymes like the pyruvate dehydroge-
nase (PDH) complex, whose activity is influenced by phosphor-
ylation, free CoA levels, and the NAD+/NADH ratio, all of which
may limit its activity relative to glycolytic flux. Glycolytic flux
may exceed the Vmax of PDH by more than an order of magnitude12 Cell Metabolism 7, January 2008 ª2008 Elsevier Inc.during cell proliferation, implying the need for a high-capacity
system to avoid accumulation of pyruvate (Curi et al., 1988). In
proliferating cells, expression of lactate dehydrogenase A
(LDH-A) solves this problem by rapidly consuming pyruvate, re-
generating NAD+ in the face of a relentless glycolytic flux while
yielding a product (lactate) that can easily be secreted (Figure 2).
LDH-A is induced by oncogenes (c-myc, HER2/neu, and others)
and by mitogen stimulation in lymphocytes, and it participates
in xenograft tumorigenicity, implying a prominent role in cell pro-
liferation (Fantin et al., 2006; Marjanovic et al., 1990; Shim et al.,
1997).
A further advantage of the high glycolytic rate is that it allows
cells to fine tune the control of biosynthetic pathways that use
intermediates derived from glucose metabolism. When a high-
flux metabolic pathway branches into a lower-flux pathway,
the ability to maintain activity of the latter is maximized when
flux through the former is highest. In proliferating cells, this has
been proposed as a way to resolve the apparent paradox
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ReviewFigure 2. Carbon Flux Differs in Quiescent versus Proliferating Cells
Quiescent cells (left) have a basal rate of glycolysis, converting glucose (glc) to pyruvate (pyr), which is then oxidized in the TCA cycle. Cells can also oxidize other
substrates like amino acids and fatty acids obtained from either the environment or the degradation of cellular macromolecules. As a result, the majority of ATP
(yellow stars) is generated by oxidative phosphorylation. During proliferation (right), the large increase in glycolytic flux generates ATP rapidly in the cytoplasm,
reducing the cytoplasmic NAD+/NADH ratio. Most of the resulting pyruvate is converted to lactate (lac) by lactate dehydrogenase A (LDH-A), which regenerates
NAD+ from NADH. The NAD+ allows glycolysis to persist, and the lactate is secreted from the cell. Some of the pyruvate is converted to acetyl-CoA (Ac-CoA) by
pyruvate dehydrogenase (PDH) and enters the TCA cycle, where it is converted into intermediates like citrate (cit) that can be used for macromolecular biosyn-
thesis. Citrate is required for the synthesis of fatty acids and cholesterol used to generate lipid membranes for daughter cells. After export to the cytoplasm, citrate
is cleaved by the enzyme ATP citrate lyase (ACL). The resulting acetyl-CoA is used by fatty acid synthase (FAS) to synthesize lipids, while the oxaloacetate (OAA) is
converted to malate (mal) by malate dehydrogenase (MDH), utilizing the low cytosolic NAD+/NADH ratio. Malate can either be returned to the mitochondria during
citrate-malate antiport or be converted to pyruvate by malic enzyme (ME), generating NADPH to be used in fatty acid synthesis.between the need for glucose-derived carbon for macromolecu-
lar synthesis and the high rate of lactate production (Newsholme
et al., 1985). Low-flux pathways in this model include those that
use glycolytic intermediates as biosynthetic precursors. The very
high rate of glycolysis allows cells to maintain biosynthetic fluxes
during rapid proliferation but results in a high rate of lactate pro-
duction.
The TCA Cycle Provides Proliferating Cells
with Biosynthetic Precursors
To synthesize lipids, proteins, and nucleic acids, cells use pre-
cursors derived from TCA cycle intermediates. Therefore,
a key role of the TCA cycle in proliferating cells is to act as a
hub for biosynthesis. This is an important difference from the me-
tabolism of nonproliferating, oxidative tissues like the heart,where the traditional view of the TCA cycle is that it serves to
derive maximal ATP production from oxidizable substrates, gen-
erating two CO2 molecules per turn. During cell proliferation,
however, much of the carbon that enters the TCA cycle is used
in biosynthetic pathways that consume rather than produce
ATP. This results in a continuous efflux of intermediates (cataple-
rosis).
Synthesis of lipids (fatty acids, cholesterol, and isoprenoids) is
a prime example of cataplerosis in proliferating cells. Glucose is
a major lipogenic substrate using the pathway highlighted in
green in the right panel of Figure 2. This pathway transfers mito-
chondrial citrate out to the cytosol to be converted to oxaloace-
tate (OAA) and the lipogenic precursor acetyl-CoA. The lipogenic
enzymes ATP citrate lyase and fatty acid synthase are induced in
tumor cells and proliferating hematopoietic cells, and theirCell Metabolism 7, January 2008 ª2008 Elsevier Inc. 13
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Reviewactivity is required for proliferation (Bauer et al., 2005; Hatzivas-
siliou et al., 2005; Kuhajda et al., 1994; Pizer et al., 1996). This
may be because a large percentage of fatty acids in the mem-
branes of proliferating cells are synthesized de novo rather
than scavenged from the extracellular environment (Kannan
et al., 1980; Ookhtens et al., 1984) or because some crucial cel-
lular lipid pool requires de novo synthesis. The export of citrate
for lipid synthesis impacts overall function of the cycle, resulting
in what some have called a ‘‘truncated’’ cycle because of the rel-
ative decrease in the fraction of mitochondrial citrate that is ox-
idized (Hatzivassiliou et al., 2005; Parlo and Coleman, 1984). The
high flux of mitochondrial citrate to cholesterol synthesis has
been studied in hepatoma cells, where proliferation is propor-
tional to the rate of citrate efflux and inversely proportional to cit-
rate-stimulated respiration (Parlo and Coleman, 1984, 1986).
Therefore, in these cholesterol-rich cells, TCA truncation ap-
pears to support cell proliferation. Other TCA cycle intermedi-
ates are used for biosynthesis of different macromolecules.
OAA and a-ketoglutarate (a-KG) supply intracellular pools of
nonessential amino acids to be used in the synthesis of proteins
and nucleotides. These activities also contribute to cataplerosis
in proliferating cells engaged in macromolecular biosynthesis.
In rare cases, the TCA cycle enzymes succinate dehydroge-
nase (SDH) and fumarate hydratase (FH) behave genetically as
tumor suppressors. Familial paraganglioma can be caused by
mutations in SDHB, SDHC, or SDHD, three of the four SDH sub-
units (Astuti et al., 2001; Baysal et al., 2000; Niemann and Muller,
2000). In affected families, a mutation in any of these genes
imposes a dominantly inherited tumor risk, with loss of the
wild-type allele in tumors. Similarly, SDHB and SDHD mutations
can cause pheochromocytoma (Astuti et al., 2001; Gimm et al.,
2000), and mutations in FH cause a dominant syndrome of uter-
ine fibroids, leiomyomata, and papillary renal cell cancer (Tomlin-
son et al., 2002). Interestingly, cells from some paragangliomas
have no residual SDH activity, implying severe impairment of
TCA cycling in those tumors (Gimenez-Roqueplo et al., 2001).
Despite this, the cells not only survive but accumulate at a path-
ologic rate. These examples are interesting exceptions to the
general finding that tumor cells contain functional TCA cycles.
Further investigations may reveal compensatory metabolic path-
ways that support this form of tumor cell growth.
Anaplerosis Allows Proliferating Cells to Use the TCA
Cycle for Biosynthesis
In order to sustain TCA cycle function in the face of cataplerosis,
cells must have a matching influx of intermediates to resupply
‘‘lost’’ OAA (anaplerosis). Citrate export for fatty acid synthesis
demonstrates this necessity: formation of another citrate mole-
cule requires an OAA produced from pyruvate or amino acids.
Anaplerosis is a critical feature of growth metabolism because
it gives cells the ability to use the TCA cycle as a supply of
biosynthetic precursors. A high anaplerotic flux is a more spe-
cific indicator of cell growth than a high glycolytic flux, because
the latter can be initiated by hypoxia and other stresses indepen-
dently of macromolecular synthesis.
There are several mechanisms that cells can use to produce
anaplerotic activity. The simplest uses pyruvate carboxylase
(PC), which generates OAA directly from pyruvate. Mitogens
enhance PC activity in lymphocytes, suggesting that PC might14 Cell Metabolism 7, January 2008 ª2008 Elsevier Inc.be part of the proliferative metabolic program in those cells
(Curi et al., 1988). But in MCF-7 breast carcinoma cells, estrogen
stimulation suppresses PC activity while enhancing proliferation
(Forbes et al., 2006). Furthermore, most hepatomas have de-
creased PC expression and activity compared to normal liver
(Chang and Morris, 1973; Hammond and Balinsky, 1978), and
the ratio of PC/PDH activity is decreased in glioma and neuro-
blastoma cells compared to normal glia and neuronal tissue
(Brand et al., 1992). Therefore, PC does not appear to be a uni-
versal component of anaplerotic flux during cell proliferation.
An alternative source of anaplerosis is through metabolism of
amino acids, particularly glutamine, the most abundant amino
acid in mammals. Proliferating cells metabolize glutamine in
multiple pathways for bioenergetics and biosynthesis (Eagle
et al., 1956; Kovacevic and McGivan, 1983). Cells can partially
oxidize glutamine in a manner analogous to the partial oxidation
of glucose during aerobic glycolysis (Reitzer et al., 1979). This
pathway (‘‘glutaminolysis’’) adds to cellular production of
NADPH and lactate (Figure 3). Unlike aerobic glycolysis, how-
ever, glutaminolysis uses several steps of the TCA cycle, leading
to general recognition of the fact that glutamine is a source of
energy for proliferating cells. It is equally important that mito-
chondrial glutamine metabolism can produce OAA, providing
a source of anaplerosis in growing cells (Figure 3). Evidence
from a variety of cell types supports this conclusion. Estrogen
stimulation induces glutaminolysis in breast cancer cells (Forbes
et al., 2006), while mitogen stimulation has similar effects in
lymphocytes (Brand, 1985). Nuclear magnetic resonance
(NMR) spectroscopy using 13C-labeled substrates has revealed
the use of glutamine as the major anaplerotic precursor in pro-
liferating glioma cells in both rats (Portais et al., 1996) and hu-
mans (DeBerardinis et al., 2007). Impressively, glutamine depri-
vation from fibroblast cultures essentially eliminates pools of the
TCA cycle intermediates fumarate and malate (Yuneva et al.,
2007). Together, these observations suggest that glutamine
metabolism allows cells to maintain a sufficient anaplerotic
flux to use a sizable fraction of TCA cycle intermediates as pre-
cursors for biosynthetic pathways. Importantly, glutamine’s
central role in multiple pathways of intermediary metabolism
that produce glutamate and a-KG (Figure 3) makes it a conve-
nient molecule for cells to use as a source of carbon for the
TCA cycle.
Regulation of Metabolic Activity in Proliferating Cells
Normal mammalian cells do not proliferate autonomously but
instead enter the cell cycle only when instructed to do so by
growth factors and downstream signaling pathways, which influ-
ence gene expression and cell physiology. Given that prolifera-
tion relies on the metabolic activities discussed above, it is not
surprising that growth-factor-stimulated signal transduction reg-
ulates these activities as well. Traditional views of intermediary
metabolism hold that metabolic activities are largely regulated
through allosteric effects of metabolites on rate-limiting en-
zymes, giving pathways self-regulatory capacity and introducing
control at branch points between intersecting pathways. While
many of these mechanisms are at work in proliferating cells,
efforts to understand the impact of signal transduction on cell
proliferation have revealed a variety of effects directed at meta-
bolic fluxes. For example, during proliferation of tumor cells and
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ReviewFigure 3. Glutamine-Dependent
Anaplerosis Allows Proliferating Cells
to Use TCA Cycle Intermediates as
Precursors for Biosynthesis
The proliferating cell shown here is using citrate for
lipid synthesis (green arrows), resulting in loss of
oxaloacetate from the TCA cycle. OAA replenish-
ment (anaplerosis) is derived from the complex
metabolism of glutamine (Gln, red arrows). In the
cytosol, glutamine donates nitrogen to purines
and pyrimidines, resulting in the formation of glu-
tamate (Glu). Glutamate donates its amino group
to a-keto acids to form nonessential amino acids
and a-ketoglutarate (a-KG), which can enter the
mitochondria. Glutamine can also be converted
to glutamate in the mitochondrial matrix by phos-
phate-dependent glutaminase (PDG), which
releases glutamine’s amido group as free ammo-
nia (red square). Mitochondrial glutamate can be
converted to a-KG by glutamate dehydrogenase
(GDH, forming another ammonia molecule) or
intramitochondrial aminotransferases. During ana-
plerosis, a-KG enters the TCA cycle and produces
OAA. In addition to its use as a source of OAA, glu-
tamine carbon can be converted to lactate (gluta-
minolysis). This process generates both NADPH
and NAD+ in the cytoplasm. Ammonia generated
during glutamine metabolism is mostly secreted
from the cell. Other abbreviations: Asp, aspartate;
Succ, succinate; AA, amino acid.lymphocytes, growth-factor signaling suppresses b-oxidation of
fatty acids, minimizing futile cycling and maximizing lipid synthe-
sis (Buzzai et al., 2005; DeBerardinis et al., 2006). In hematopoi-
etic cells, this requires a specific inhibitory effect of the PI3K/Akt
signaling pathway on the expression of carnitine palmitoyltrans-
ferase IA, the rate-limiting enzyme in b-oxidation (DeBerardinis
et al., 2006). Therefore, growth-factor signaling can reorganize
metabolic fluxes independently of traditional allosteric mecha-
nisms of pathway regulation.
Generating high fluxes of glycolysis and glutaminolysis largely
depends on increasing cellular uptake of glucose and glutamine.
Proliferating cells rely on growth-factor signaling to generate
these fluxes because a primary effect of signaling is to enhance
nutrient capture from the extracellular environment (Figure 1). In
fact, in the absence of growth-factor signaling, mammalian cells
rapidly lose nutrient transporter expression and cannot maintain
sufficient cell-autonomous nutrient uptake for basal bioenerget-
ics and replacement macromolecular synthesis. Instead, they
turn to a form of ‘‘self-cannibalism’’ termed autophagy, which
provides a limited supply of substrates generated from macro-
molecular degradation to maintain ATP production for cell
survival (Figure 1) (Lum et al., 2005).
The mechanisms that integrate signal transduction and cell
metabolism are largely conserved between normal cells and
cancer cells. The major difference is that in normal cells, initiation
of signaling requires extracellular stimulation, while cancer cells
often have mutations that chronically enhance these pathways,
allowing them to maintain a metabolic phenotype of biosynthe-
sis independently of normal physiologic constraints. In other
words, cancer cells have increased metabolic autonomy. Below,
we discuss a few mechanisms that integrate cell signaling and
key aspects of metabolism during physiologic cell proliferation
and tumorigenesis. Together, activities of the PI3K/Akt/mTOR
pathway and effects of the transcription factors HIF-1a andMyc appear to regulate complementary aspects of cellular
metabolism (Figure 4).
The PI3K/Akt/mTOR Pathway Is a Master Regulator of
Aerobic Glycolysis and Cellular Biosynthesis
The PI3K/Akt/mTOR pathway is a highly conserved, widely
expressed system used by cells to respond to growth factors
(Franke et al., 2003). Binding of a growth factor to its surface re-
ceptor activates PI3K, resulting in phosphorylation of phospha-
tidylinositol lipids at the plasma membrane. These are involved
in recruitment and/or activation of downstream effectors, partic-
ularly the serine/threonine kinases Akt and mTOR. Activation of
the PI3K/Akt/mTOR pathway in growth-factor-dependent cells
and tumor cells enhances many of the metabolic activities that
support cellular biosynthesis (Figure 4). First, it permits cells to
increase the surface expression of nutrient transporters,
enabling increased uptake of glucose, amino acids, and other
nutrients (Barata et al., 2004; Edinger and Thompson, 2002;
Roos et al., 2007; Wieman et al., 2007; Xu et al., 2005). Second,
through effects on gene expression and enzyme activity, Akt
increases glycolysis and lactate production and is sufficient to
induce a Warburg effect in either nontransformed cells or cancer
cells (Elstrom et al., 2004; Plas et al., 2001; Rathmell et al., 2003).
Third, activation of this pathway enhances the biosynthesis of
macromolecules. PI3K and Akt stimulate expression of lipogenic
genes and lipid synthesis in numerous cell types (Bauer et al.,
2005; Chang et al., 2005), while mTOR is a key regulator of
protein translation (Gingras et al., 2001).
In normal cells, activation of the PI3K system is tightly con-
trolled by dephosphorylation of phosphatidylinositol species
by the phosphatase PTEN. But in malignancies, activity of the
pathway can be augmented through a variety of mechanisms,
which together constitute one of the most prevalent classes
of mutations in human tumors (Table 1). These mutations acti-
vate PI3K, eliminate activity of negative regulators (e.g., PTEN),
Cell Metabolism 7, January 2008 ª2008 Elsevier Inc. 15
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ReviewFigure 4. A Signaling Network to Regulate Metabolism in Proliferating Cells
The model shows some of the prominent aspects of metabolism in proliferating cells, including glycolysis; lactate production; the use of TCA cycle intermediates
as macromolecular precursors; and the biosynthesis of proteins, nucleotides, and lipids. The PI3K/Akt/mTOR pathway, HIF-1a, and Myc participate in various
facets of this metabolic phenotype. The binding of a growth factor (GF) to its surface receptor brings about activation of PI3K and the serine/threonine kinases Akt
and mTOR (top left). Constitutive activation of the pathway can occur in tumors due to mutation of the tumor suppressors PTEN, TSC1, and TSC2, or by other
mechanisms (see text). Metabolic effects of the PI3K/Akt/mTOR pathway include enhanced uptake of glucose and essential amino acids and protein translation.
The transcription factor HIF-1a (bottom) is involved in determining the manner in which cells utilize glucose carbon. Translation of HIF-1a is enhanced during
growth-factor stimulation of the PI3K/Akt/mTOR pathway. In the presence of oxygen, HIF-1a is modified by prolyl hydroxylases, which target it to a ubiquitin
ligase complex that includes the tumor suppressor VHL. This association results in constitutive normoxic degradation of the HIF-1a protein. Hypoxia, mutation
of VHL, or accumulation of reactive oxygen species (ROS) or the TCA cycle intermediates succinate and fumarate impair HIF-1a degradation, allowing it to enter
the nucleus and engage in transcriptional activity. Transcriptional targets include genes encoding glucose transporter 1 (GLUT1), LDH-A, and PDK1. The com-
bined effect on glucose metabolism is to increase both glucose utilization and lactate production, as PDK1 inhibits conversion of pyruvate to acetyl-CoA by py-
ruvate dehydrogenase (PDH). The transcription factor Myc (top right) increases expression of many metabolic enzymes, including glycolytic enzymes, LDH-A,
and several enzymes required for nucleotide biosynthesis. Abbreviations: PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; TSC,
tuberous sclerosis complex; mTOR, mammalian target of rapamycin; glc-6-P, glucose-6-phosphate; 3-PG, 3-phosphoglycerate; PDK1, pyruvate dehydroge-
nase kinase 1; SDH, succinate dehydrogenase; FH, fumarate hydratase; HIF-1a, hypoxia-inducible factor 1a; VHL, von Hippel-Lindau.or introduce enhanced activities to stimulate the system (BCR-
ABL, HER2/neu amplification, etc). Regardless of the mutation,
activation of Akt is likely the most important signaling event in
terms of cell metabolism, because Akt is sufficient to drive gly-
colysis and lactate production and to suppress macromolecular
degradation in cancer cells (Buzzai et al., 2005; Elstrom et al.,
2004).
HIF-1 Signaling Regulates Glucose Metabolism
in Response to Hypoxia and Growth Factors
Decreased oxygen availability (hypoxia) stimulates cells to con-
sume glucose and produce lactate. In mammalian cells, this
response is coordinated by the hypoxia-inducible factor 1
(HIF-1) transcription factor complex (Gordan and Simon, 2007;
Semenza, 2003). HIF-1’s targets include genes encoding glucose
transporters, glycolytic enzymes, and LDH-A (O’Rourke et al.,
1996; Semenza et al., 1994). HIF-1 activity requires the subunit
16 Cell Metabolism 7, January 2008 ª2008 Elsevier Inc.HIF-1a, which is expressed under the control of growth-factor sig-
naling, in particular the PI3K/Akt/mTOR pathway (Cramer et al.,
2003; Jiang et al., 2001; Majumder et al., 2004). During normoxia,
HIF-1a undergoes a posttranslational modification by prolyl
hydroxylation, which promotes association with the von Hippel-
Lindau (VHL) tumor suppressor, targeting HIF-1a for ubiquitina-
tion and degradation (Figure 4). During hypoxia, prolyl hydroxyl-
ation is inhibited by a process involving reactive oxygen species
(ROS) generated in the mitochondria, resulting in stabilization of
the HIF-1a protein and transcriptional activity of the HIF-1 com-
plex (Brunelle et al., 2005; Guzyet al., 2005; Mansfield et al., 2005).
Constitutive cellular stabilization of HIF-1a during normoxia
can occur in tumors as a result of mutations in the tumor sup-
pressor VHL. Other mutations in SDH and FH stabilize HIF-1a
by interfering with prolyl hydroxylation, which is inhibited by ac-
cumulation of succinate or fumarate (Isaacs et al., 2005; Pollard
Cell Metabolism
ReviewTable 1. Selected Tumorigenic Mutations that Activate PI3K or Its Effectors
Gene Mutation Cancer Frequency Reference
PIK3CA Activating point
mutations
Breast 25% Bachman et al. (2004)
Colon >30% Samuels et al. (2004)
Amplification Head and neck >35% Pedrero et al. (2005)
Akt2 Amplification Ovary 12% Bellacosa et al. (1995)
Head and neck 30% Pedrero et al. (2005)
PTEN Mutation, loss of
heterozygosity
Glioma %40% Knobbe et al. (2002);
Ohgaki (2005)





>90% Kurzrock et al. (2003)
Acute lymphocytic
leukemia
20% Kurzrock et al. (2003)
HER2/neu Gene amplification Breast 25% Slamon et al. (1989)
EGFR Gene amplification,
increased expression
Lung (non-small cell) >50% Cappuzzo et al. (2005)et al., 2007; Selak et al., 2005). In tumors with mutations in VHL,
FH, or SDH subunits, constitutive (normoxic) expression of HIF-1
target genes likely contributes to aerobic glycolysis.
Although HIF-1’s role in promoting glycolysis is clear, recent
data suggest that it does not promote biosynthesis at the cellular
level. HIF-1 induces expression of pyruvate dehydrogenase
kinase 1 (PDK1), which phosphorylates and inhibits the PDH
complex (Kim et al., 2006; Papandreou et al., 2006). This limits
entry of glycolytic carbon into the TCA cycle and increases con-
version of pyruvate to lactate. This adaptation may be important
for cell survival during hypoxia, but it would impose a barrier to
proliferating cells, which rely on the availability of TCA cycle in-
termediates for biosynthesis. Recent studies in hematopoietic
cells support this hypothesis (Lum et al., 2007). In these cells,
growth-factor stimulation is required for cells to express
HIF-1a, which in turn is required to regulate the intracellular
fate of glucose-derived carbon. During normoxia, reducing
HIF-1a expression with RNA interference increases lipid synthe-
sis, cell size, and rate of proliferation. Together, these observa-
tions argue for more general metabolic functions of HIF-1 than
its conventional role as a reactionary mediator during tissue hyp-
oxia, extending its influence into the arena of growth-factor-reg-
ulated orchestration of intermediary metabolic fluxes. In this
context, it appears to act as a rheostat on mitochondrial metab-
olism, fine tuning entry of carbon into the TCA cycle. Perhaps
during the large increase in glycolytic flux that occurs during
growth-factor stimulation, this allows cells to match TCA cycle
flux with maximal electron transport chain capacity so as to
diminish oxidative stress.
Does c-Myc Regulate Metabolic Activities
Needed for the G1/S Transition?
The metabolic activity that distinguishes cell growth (i.e., in-
crease in cell biomass per se) from proliferation is duplication
of the genome, which requires a massive commitment to nucle-
otide biosynthesis by the cell. Compared to glycolytic flux, the
regulation of de novo nucleotide biosynthetic pathways by cell
signaling is poorly understood. These complex pathways rely
on coordination of multiple fluxes involving glucose, glutamine,several nonessential amino acids, and the cellular one-carbon
pool.
The myc family of genes (c-myc, L-myc, s-myc, and N-myc),
commonly amplified in human tumors, encode transcription
factors that regulate growth and cell-cycle entry by inducing ex-
pression of genes required for these processes. In normal cells,
mitogen stimulation leads to a burst of c-Myc expression in G1
phase, facilitating entry into S phase in part by activating expres-
sion of cyclins and CDK4 (Adhikary and Eilers, 2005). Like other
oncogenic transcription factors, targets of c-Myc include glyco-
lytic enzymes and LDH-A (Osthus et al., 2000; Shim et al., 1997).
However, c-Myc also induces expression of enzymes involved in
nucleotide and one-carbon metabolism, without which cells could
not successfully complete S phase (Figure 4). These include ino-
sine 50-monophosphate dehydrogenase (Guo et al., 2000), ser-
ine hydroxymethyltransferase (Nikiforov et al., 2002), adenosine
kinase, adenylate kinase 2, and phosphoribosyl pyrophosphate
amidotransferase (O’Connell et al., 2003). These data suggest
that c-Myc reinforces the effects of growth-factor signaling on
glucose metabolism and also exerts control over specialized
metabolic activities needed to duplicate the genome.
In addition, recent work has demonstrated that some c-Myc-
transformed cells have an absolute requirement for glutamine
in order to maintain viability (Yuneva et al., 2007). Depriving these
cells of glutamine results in depletion of TCA cycle intermedi-
ates, suggesting an increased need for glutamine-based anaple-
rosis during c-Myc activity. Perhaps this is a consequence of the
metabolic shift toward de novo nucleotide biosynthesis, which
requires glutamine as a nitrogen source and glucose as a carbon
source. The resulting increased availability of glutamine carbon
skeletons coupled with the reduced availability of glucose
carbon might limit the utility of PC as an anaplerotic mechanism
during peak nucleotide biosynthesis.
Future Directions: Cell Proliferation, Signal
Transduction, Metabolism, and Systems Biology
As summarized above, the emerging view of metabolic regula-
tion in proliferating cells is that signal transduction pathways
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Reviewand transcriptional networks participate in a major reorganiza-
tion of metabolic activities into a platform that supports bioener-
getics, macromolecular synthesis, and ultimately cell division.
Efforts to integrate modern concepts of signal transduction
with cellular metabolism are still in their infancy. The current chal-
lenge is to develop broad, systems-based approaches devoted
to integrating information from previously disparate areas of in-
quiry so that a more complete understanding of the metabolic
phenotype of cell proliferation will emerge. This will require
a new set of tools combining, at a minimum, molecular biology
and metabolic flux analysis so as to determine the impact of ma-
nipulating signaling mediators on specific and global metabolic
activities.
One area that needs to be addressed is the regulation of ana-
plerosis and of mitochondrial metabolism in general. This impor-
tant matter has so far escaped the scrutiny directed at aerobic
glycolysis in the 80-plus years since Warburg’s observations.
The models of cell metabolism proposed here predict that
biosynthetic fluxes using TCA cycle intermediates are matched
on a mole-per-mole basis by anaplerotic fluxes. Determining
whether this hypothesis is correct and how such fluxes are reg-
ulated will be an important piece in the biological puzzle of cell
proliferation.
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